## Abdel-Rahman N Zekri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9066910/publications.pdf

Version: 2024-02-01

114 papers 2,533 citations

172207 29 h-index 253896 43 g-index

119 all docs

119 docs citations

119 times ranked 4224 citing authors

#	Article	IF	CITATIONS
1	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. Science, 2021, 374, 423-431.	6.0	144
2	Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterology, 2004, 4, 22.	0.8	112
3	Autologous Hematopoietic Stem Cell Transplantation in 48 Patients with End-Stage Chronic Liver Diseases. Cell Transplantation, 2010, 19, 1475-1486.	1.2	108
4	Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Research and Therapy, 2014, 5, 70.	2.4	98
5	Autologous CD34 <sup>+</sup> and CD133 <sup>+</sup> stem cells transplantation in patients with end stage liver disease. World Journal of Gastroenterology, 2010, 16, 5297.	1.4	85
6	Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection. Tumor Biology, 2016, 37, 12273-12286.	0.8	79
7	Concordance of DNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. Experimental and Molecular Pathology, 2010, 88, 107-111.	0.9	71
8	MicroRNAs and Metastasis-related Gene Expression in Egyptian Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2012, 13, 591-598.	0.5	68
9	Circulating Serum miRNAs as Diagnostic Markers for Colorectal Cancer. PLoS ONE, 2016, 11, e0154130.	1.1	61
10	Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World Journal of Gastroenterology, 2005, 11, 6624.	1.4	54
11	Transforming growth factor- $\hat{l}^2$ , insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: Prognostic and predictive markers in triple-negative and non-triple-negative breast cancer. Molecular Medicine Reports, 2015, 12, 851-864.	1.1	46
12	The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency. Stem Cell Research and Therapy, 2015, 6, 118.	2.4	44
13	The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma. BMC Clinical Pathology, 2007, 7, 4.	1.8	42
14	Correlation between p53 mutations and HPV in bilharzial bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2003, 21, 334-341.	0.8	40
15	Hepatitis B virus (HBV) genotypes in Egyptian pediatric cancer patients with acute and chronic active HBV infection. Virology Journal, 2007, 4, 74.	1.4	39
16	Consensus siRNA for inhibition of HCV genotype-4 replication. Virology Journal, 2009, 6, 13.	1.4	39
17	Epstein-Barr virus and breast cancer: Epidemiological and Molecular study on Egyptian and Iraqi women. Journal of the Egyptian National Cancer Institute, 2012, 24, 123-131.	0.6	39
18	Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation. Transplant Immunology, 2004, 13, 305-311.	0.6	38

#	Article	IF	Citations
19	Methylation of multiple genes in hepatitis C virus associated hepatocellular carcinoma. Journal of Advanced Research, 2014, 5, 27-40.	4.4	38
20	Occult HBV infection among Egyptian hepatocellular carcinoma patients. Virology Journal, 2011, 8, 90.	1.4	37
21	Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma. Journal of Medical Microbiology, 2000, 49, 89-95.	0.7	35
22	Human papillomavirus infection in Egyptian esophageal carcinoma: Correlation with p53, p21waf, mdm2, C-erbB2 and impact on survival. Pathology International, 2005, 55, 53-62.	0.6	34
23	Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data. Translational Research, 2015, 165, 396-406.	2.2	34
24	Antioxidant activity and apoptotic induction as mechanisms of action of <i>Withania somnifera</i> (Ashwagandha) against a hepatocellular carcinoma cell line. Journal of International Medical Research, 2018, 46, 1358-1369.	0.4	32
25	Impact of Global DNA Methylation in Treatment Outcome of Colorectal Cancer Patients. Frontiers in Pharmacology, 2018, 9, 1173.	1.6	32
26	Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease. World Journal of Gastroenterology, 2014, 20, 18240.	1.4	32
27	Differentially Expressed Genes in Metastatic Advanced Egyptian Bladder Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3543-3549.	0.5	32
28	TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4. Journal of Medical Virology, 2005, 75, 412-420.	2.5	31
29	Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comparative Hepatology, 2010, 9, 1.	0.9	31
30	Disease Progression from Chronic Hepatitis C to Cirrhosis and Hepatocellular Carcinoma is Associated with Increasing DNA Promoter Methylation. Asian Pacific Journal of Cancer Prevention, 2013, 14, 6721-6726.	0.5	31
31	Prognostic significance of circulating tumor cells (CTCs) in Egyptian non-metastatic colorectal cancer patients: A comparative study for four different techniques of detection (Flowcytometry,) Tj ETQq1 1 0.78 2019, 106, 90-101.	34314 rgE 0.9	BT <u> O</u> verlock
32	Mismatch repair genes (hMLH1,hPMS1,hPMS2,GTBP/hMSH6,hMSH2) in the pathogenesis of hepatocellular carcinoma. World Journal of Gastroenterology, 2005, 11, 3020.	1.4	29
33	Genetic profile of Egyptian hepatocellular-carcinoma associated with hepatitis C virus Genotype 4 by 15 K cDNA microarray: Preliminary study. BMC Research Notes, 2008, 1, 106.	0.6	28
34	The prognostic value of <i>câ€Kit</i> , <i>Kâ€ras</i> codon 12, and <i>p53</i> codon 72 mutations in Egyptian patients with stage II colorectal cancer. Cancer, 2010, 116, 4954-4964.	2.0	28
35	Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt. Experimental and Molecular Pathology, 2015, 99, 303-311.	0.9	27
36	Expression of pro―and anti―nflammatory cytokines in relation to apoptotic genes in Egyptian liver disease patients associated with HCVâ€genotypeâ€4. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 416-428.	1.4	26

#	Article	IF	CITATIONS
37	Molecular Prognostic Profile of Egyptian HCC Cases Infected with Hepatitis C Virus. Asian Pacific Journal of Cancer Prevention, 2012, 13, 5433-5438.	0.5	26
38	Genetic distance and heterogenecity between quasispecies is a critical predictor to IFN response in Egyptian patients with HCV genotype-4. Virology Journal, 2007, 4, 16.	1.4	24
39	Cancer in Africa: Is It a Genetic or Environmental Health Problem?. Frontiers in Oncology, 2020, 10, 604214.	1.3	24
40	Positional effect of mutations in 5'UTR of hepatitis C virus 4a on patients' response to therapy. World Journal of Gastroenterology, 2009, 15, 1480.	1.4	22
41	Differential expression of p53 family proteins in colorectal adenomas and carcinomas: Prognostic and predictive values. Histology and Histopathology, 2014, 29, 207-16.	0.5	21
42	Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer. BMC Cancer, 2009, 9, 32.	1.1	20
43	Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence. Medical Oncology, 2010, 27, 1286-1294.	1.2	20
44	Serum levels of $\hat{l}^2$ -catenin as a potential marker for genotype 4/hepatitis C-associated hepatocellular carcinoma. Oncology Reports, 2011, 26, 825-31.	1.2	20
45	Characterization of chronic HCV infection-induced apoptosis. Comparative Hepatology, 2011, 10, 4.	0.9	19
46	Arabinoxylan rice bran (Biobran) suppresses the viremia level in patients with chronic HCV infection: A randomized trial. International Journal of Immunopathology and Pharmacology, 2016, 29, 647-653.	1.0	19
47	Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions. World Journal of Gastroenterology, 2018, 24, 1228-1238.	1.4	19
48	Evaluation of simian virusâ€40 as a biological prognostic factor in Egyptian patients with malignant pleural mesothelioma. Pathology International, 2007, 57, 493-501.	0.6	18
49	Human Papillomavirus Genotypes and Methylation of CADM1, PAX1, MAL and ADCYAP1 Genes in Epithelial Ovarian Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2017, 18, 169-176.	0.5	18
50	Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients. Experimental and Molecular Pathology, 2012, 93, 154-161.	0.9	17
51	Detection of Human Cytomegalovirus in Malignant and Benign Breast Tumors in Egyptian Women. Clinical Breast Cancer, 2018, 18, e629-e642.	1.1	17
52	The possible role of Dickkopf-1, Golgi protein- 73 and Midkine as predictors of hepatocarcinogenesis: a review and an Egyptian study. Scientific Reports, 2020, 10, 5156.	1.6	17
53	Human Papilloma Virus Infection and Overexpression of P53 Protein in Bilharzial Bladder Cancer. Tumori, 2001, 87, 256-261.	0.6	16
54	Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6923-6928.	0.5	16

#	Article	IF	CITATIONS
55	Lack of association between genotypes and subtypes of HCV and occurrence of hepatocellular carcinoma in Egypt. Journal of Medical Virology, 2009, 81, 844-847.	2.5	15
56	Polymorphisms of base-excision repair genes and the hepatocarcinogenesis. Gene, 2018, 675, 62-68.	1.0	15
57	Genomic characterization of SARS-CoV-2 in Egypt. Journal of Advanced Research, 2021, 30, 123-132.	4.4	15
58	MiRNAs as molecular biomarkers in stage II egyptian colorectal cancer patients. Experimental and Molecular Pathology, 2018, 105, 260-271.	0.9	14
59	The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion. BMC Cancer, 2017, 17, 329.	1.1	13
60	Targeted next generation sequencing identifies somatic mutations in a cohort of Egyptian breast cancer patients. Journal of Advanced Research, 2020, 24, 149-157.	4.4	13
61	Serum Biomarkers for Early Detection of Hepatocellular Carcinoma Associated with HCV Infection in Egyptian Patients. Asian Pacific Journal of Cancer Prevention, 2015, 16, 1281-1287.	0.5	13
62	Detection of simian virus 40 DNA sequences in Egyptian patients with different hematological malignancies. Leukemia and Lymphoma, 2007, 48, 1828-1834.	0.6	12
63	BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. Oncotarget, 2017, 8, 10114-10135.	0.8	12
64	Dynamic interplay between CXCL levels in chronic Hepatitis C patients treated by Interferon. Virology Journal, 2013, 10, 218.	1.4	11
65	Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial—an update. Medical Oncology, 2014, 31, 811.	1.2	11
66	Characterization of the SARS-CoV-2 genomes in Egypt in first and second waves of infection. Scientific Reports, 2021, 11, 21632.	1.6	11
67	The role of cyclins and cyclin dependent kinases in development and progression of hepatitis C virus-genotype 4-associated hepatitis and hepatocellular carcinoma. Experimental and Molecular Pathology, 2011, 91, 643-652.	0.9	10
68	Promotor methylation: Does it affect response to therapy in chronic hepatitis C (G4) or fibrosis?. Annals of Hepatology, 2014, 13, 518-524.	0.6	10
69	The Role of Breast Cancer Stem Cells and Some Related Molecular Biomarkers in Metastatic and Nonmetastatic Breast Cancer. Clinical Breast Cancer, 2020, 20, e373-e384.	1.1	10
70	IL28B rs12979860 Gene Polymorphism in Egyptian Patients with Chronic Liver Disease Infected with HCV. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7213-7218.	0.5	10
71	Alterations of the fragile histidine triad gene in hepatitisâ€∫C virus-associated hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 87-94.	1.4	9
72	Hepatitis C virus-NS3P in relation to p53, p21waf, mdm2, p21-ras and c-erbB2 in hepatocarcinogenesis. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1731-1740.	1.4	9

#	Article	IF	CITATIONS
73	Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas. Leukemia and Lymphoma, 2014, 55, 1158-1165.	0.6	9
74	Gene expression profiling of circulating CD133 + cells of hepatocellular carcinoma patients associated with HCV infection. Journal of the Egyptian National Cancer Institute, 2017, 29, 19-24.	0.6	9
75	The role of E-cadherin and Runx3 in Helicobacter Pylori – Associated gastric carcinoma is achieved through regulating P21waf and P27 expression. Cancer Genetics, 2018, 228-229, 64-72.	0.2	9
76	MicroRNA Signatures for circulating CD133-positive cells in hepatocellular carcinoma with HCV infection. PLoS ONE, 2018, 13, e0193709.	1.1	9
77	Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1. European Journal of Gastroenterology and Hepatology, 2010, 22, 450-456.	0.8	8
78	Caspase recruitment domains. New potential markers for diagnosis of hepatocellular carcinoma associated with HCV in Egyptian patients. Annals of Hepatology, 2013, 12, 774-781.	0.6	8
79	Hepatitis C Virus Hypervariable Region 1 Variants Presented on Hepatitis B Virus Capsid-Like Particles Induce Cross-Neutralizing Antibodies. PLoS ONE, 2014, 9, e102235.	1.1	8
80	The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt. Diagnostic Pathology, 2020, 15, 10.	0.9	8
81	BRCA1 and BRCA2 truncating mutations and variants of unknown significance in Egyptian female breast cancer patients. Clinica Chimica Acta, 2021, 512, 66-73.	0.5	8
82	Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures. Leukemia and Lymphoma, 2013, 54, 996-1003.	0.6	7
83	Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions. Oncology Letters, 2016, 12, 2782-2788.	0.8	7
84	The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma. Molecular Biology Reports, 2019, 46, 4063-4076.	1.0	7
85	Microsatellite instability profiling in Egyptian bladder cancer patients: A pilot study. Current Problems in Cancer, 2019, 43, 100472.	1.0	7
86	Genome sequencing of SARS-CoV-2 in a cohort of Egyptian patients revealed mutation hotspots that are related to clinical outcomes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166154.	1.8	7
87	p53 mutation in HCV-genotype-4 associated hepatocellular carcinoma in Egyptian patients. Journal of the Egyptian National Cancer Institute, 2006, 18, 17-29.	0.6	7
88	The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value. Molecular Biology Reports, 2018, 45, 2025-2035.	1.0	6
89	The role of circulating tumor cells and K-ras mutations in patients with locally advanced rectal cancer: a prospective study. Molecular Biology Reports, 2020, 47, 9645-9657.	1.0	6
90	Prevalence of MMTV-Like env Sequences and Its Association with BRCA1/2 Genes Mutations Among Egyptian Breast Cancer Patients. Cancer Management and Research, 2021, Volume 13, 2835-2848.	0.9	6

#	Article	IF	Citations
91	Application of refractory fragment amplification system for detection of Egyptian variant of Familial Mediterranean Fever. The Egyptian Journal of Immunology / Egyptian Association of Immunologists, 2004, 11, 103-10.	0.1	5
92	Androgen profiles among Egyptian adults considering liver status. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e137-e145.	1.4	4
93	The Core/E1 domain of hepatitis C virus genotype 4a in Egypt does not contain viral mutations or strains specific for hepatocellular carcinoma. Journal of Clinical Virology, 2011, 52, 333-338.	1.6	4
94	Caspase recruitment domains. New potential markers for diagnosis of hepatocellular carcinoma associated with HCV in Egyptian patients. Annals of Hepatology, 2013, 12, 774-81.	0.6	4
95	Promotor methylation: does it affect response to therapy in chronic hepatitis C (G4) or fibrosis?. Annals of Hepatology, 2014, 13, 518-24.	0.6	4
96	Multigene Panel Sequencing Reveals Cancer-Specific and Common Somatic Mutations in Colorectal Cancer Patients: An Egyptian Experience. Current Issues in Molecular Biology, 2022, 44, 1332-1352.	1.0	4
97	Identification of Different miRNAs and Their Relevant miRNA Targeted Genes Involved in Sister Chromatid Cohesion and Segregation (SCCS)/chromatin Remodeling Pathway on T1G3 Urothelial Carcinoma (UC) Response to BCG Immunotherapy. Clinical Genitourinary Cancer, 2022, 20, e181-e189.	0.9	4
98	New insight into HCV E1/E2 region of genotype 4a. Virology Journal, 2014, 11, 231.	1.4	3
99	HLA alleles in Egyptian HCV genotype-4 carriers. The Egyptian Journal of Immunology / Egyptian Association of Immunologists, 2005, 12, 77-86.	0.1	3
100	Estrogen Receptor Gene Polymorphism as a Possible Genetic Risk Factor for Treatment Response in ER-Positive Breast Cancer Patients. Biochemical Genetics, 2022, 60, 1963-1985.	0.8	3
101	Whole-genome sequencing of human Pegivirus variant from an Egyptian patient co-infected with hepatitis C virus: a case report. Virology Journal, 2019, 16, 132.	1.4	2
102	Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients. Biology, 2021, 10, 566.	1.3	2
103	The Clinical Significance of Promoter Methylation of Fluoropyrimidine Metabolizing and Cyclooxygenase Genes in Colorectal Cancer. Epigenetics Insights, 2021, 14, 251686572098623.	0.6	2
104	Role of human papilloma virus (HPV) in common and genital warts and its relation to P53 expression. Journal of the Egyptian National Cancer Institute, 2006, 18, 117-24.	0.6	2
105	E1/E2 of Hepatitis C Virus Genotype4 and Apoptosis. Asian Pacific Journal of Cancer Prevention, 2016, 17, 3131-8.	0.5	2
106	Epstein–Barr virus and Interleukin-28B polymorphism in the prediction of response to interferon therapy in hepatitis C patients. Arab Journal of Gastroenterology, 2015, 16, 84-89.	0.4	1
107	Fluoropyrimdine therapy induced alterations in interleukins expression in colorectal cancer patients. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842110083.	1.0	1
108	Prognostic influence of microsatellite alterations of muscle-invasive bladder cancer treated with radical cystectomy. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 64.e9-64.e15.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Potential Diagnostic and Prognostic Value of Lymphocytic Mitochondrial DNA Deletion in Relation to Folic Acid Status in HCV-Related Hepatocellular Carcinoma. Asian Pacific Journal of Cancer Prevention, 2017, 18, 2451-2457.	0.5	1
110	The Molecular Background Associated with the Progression of Hepatitis C to Hepatocellular Carcinoma. , 0, , .		O
111	Assessment of the Circulating Tumor Cells and Microsatellite Instability in Colorectal Cancer Patients: Prognostic and Diagnostic Value. OncoTargets and Therapy, 2021, Volume 14, 1937-1951.	1.0	O
112	Combining Bevacizumab with knocked-down $\hat{l}^2$ -catenin reduces VEGF-A and Slug mRNA in HepG2 but not in Caco-2 cell lines. Current Molecular Medicine, 2021, 21, .	0.6	0
113	Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: A randomized phase II trial: An update Journal of Clinical Oncology, 2013, 31, 4537-4537.	0.8	O
114	Assessment of the diagnostic value of microsatellite instability in the urine of bladder cancer patients Journal of Clinical Oncology, 2019, 37, 384-384.	0.8	0